gms | German Medical Science

24th Annual Meeting of the German Retina Society

German Retina Society

17.06. - 18.06.2011, Aachen

Article

Send article

Intravitreous injection of bevacizumab in radiation maculopathy after brachytherapy of malignant melanoma

Meeting Abstract

Search Medline for

  • Rainer Guthoff - Universitäts-Augenklinik Würzburg
  • C. von Strachwitz - Universitäts-Augenklinik Würzburg
  • T. Guthoff - Universitäts-Augenklinik Würzburg
  • T. Meyer-ter-Vehn - Universitäts-Augenklinik Würzburg
  • W. Göbel - Universitäts-Augenklinik Würzburg

German Retina Society. 24th Annual Conference of the German Retina Society. Aachen, 17.-18.06.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11rg22

doi: 10.3205/11rg22, urn:nbn:de:0183-11rg228

This is the English version of the article.
The German version can be found at: http://www.egms.de/de/meetings/rg2011/11rg22.shtml

Published: June 15, 2011

© 2011 Guthoff et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Purpose: To investigate the benefit of bevacizumab in radiation retinopathy, which is a common sight-threatening complication of brachytherapy for malignant melanoma.

Methods: In this retrospective study we included 9 consecutive patients who developed macular edema after brachytherapy and were followed up 3 months after triple intravitreal injection of bevacizumab. Best corrected visual acuity (BCVA), biomicroscopic indirect fundus examination and OCT findings were evaluated.

Results: The mean pre-treatment visual acuity was 0.15 (standard deviation [SD]±0.12), the mean central macular thickness (CMT) measured in OCT was 560 µm (SD±133.9 µm). After 3 months the mean visual acuity was 0.2 (SD±0.22), CMT 453 µm (SD±101 µm). Stabilization (0±2 lines) or improvement of BCVA was obtained in 7 eyes.

Discussion: From our retrospective pilot study, there is strong indication that bevacizumab is able to stabilize visual acuity in macular edema in radiation retinopathy.